Information Provided By: 
Fly News Breaks for July 6, 2016
SRPT
Jul 6, 2016 | 07:43 EDT
Janney Capital believes that Sarepta has completed the additional analysis requested by the FDA four weeks ago. The firm says that the company would have released any significant negative data uncovered by the additional analysis. Janney believes that the stock could get a boost from short covering if the company does not release any additional negative news over the next two weeks. The firm continues to expect the FDA to grant the company's drug accelerated approval status.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
